Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2010
06/03/2010US20100137244 Preparation and utility of hmg-coa reductase inhibitors
06/03/2010US20100137239 Gemcitabine combination therapy
06/03/2010US20100137237 Process for the preparation of an (rp)-8-substituted camps
06/03/2010US20100137236 Compositions Comprising a GPR109 Ligand For Treating Disorders of the Digestive Tract and/or Cancer
06/03/2010US20100137221 Peptides that interact with topoisomerase i and methods thereof
06/03/2010US20100137208 Intratumorally administered lactoferrin in the treatment of malignantneoplasms and other hyperproliferative diseases
06/03/2010US20100137207 G protein coupled receptor agonists and antagonists and methods of activating and inhibiting g protein coupled receptors using the same
06/03/2010US20100137198 Pharmaceutical composition for topical application
06/03/2010US20100137196 Histone deacetylases, and uses related thereto
06/03/2010US20100137187 Glutamate-Enhanced Cell-Penetrating Peptides and Methods of Using Same
06/03/2010US20100136695 Double-stranded oligonucleotides
06/03/2010US20100136628 competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells
06/03/2010US20100136581 Diagnosis and treatment of malignant neoplasms
06/03/2010US20100136577 Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
06/03/2010US20100136575 B7-related nucleic acids and polypeptides useful for immunomodulation
06/03/2010US20100136522 Endogenous retroviruses up-regulated in prostate cancer
06/03/2010US20100136139 Cancer marker and therapeutic agent for cancer
06/03/2010US20100136138 Treatment of lung cancer
06/03/2010US20100136137 Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
06/03/2010US20100136136 JAK-2 Modulators and Methods of Use
06/03/2010US20100136116 Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
06/03/2010US20100136115 Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation
06/03/2010US20100136108 Formulation for retinoid-containing soft gelatin capsules
06/03/2010US20100136101 Compositions and methods for sirna inhibition of hif-1 alpha
06/03/2010US20100136100 Removal promoters and inhibitor for apoptosis cells in vivo
06/03/2010US20100136099 Liposome for induction of cell-mediated immunity
06/03/2010US20100136061 Light-mediated anti-cell proliferative compositions and methods
06/03/2010US20100136043 Composition comprising immunogenic microparticles
06/03/2010US20100136042 Globo h and related anti-cancer vaccines with novel glycolipid adjuvants
06/03/2010US20100136036 Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions
06/03/2010US20100136033 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
06/03/2010US20100136031 Anti-cxcr1 compositions and methods
06/03/2010US20100136029 Use of Tri-Substituted Glycerol Compounds for the Treatment of Hematological Malignancies
06/03/2010US20100136021 Tgf-beta binding antibodies
06/03/2010US20100136020 Uses of il-174 antagonists for inhibiting a th2 immune response
06/03/2010US20100136019 Modulating regulatory t cell activity via interleukin 35
06/03/2010US20100136017 Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
06/03/2010US20100136016 Heat shock proteins from mycobacterium leprae and uses thereof
06/03/2010US20100136014 GIPs, a Family of Polypeptides with Transcription Factor Activity that Interact with Goodpasture Antigen Binding Protein
06/03/2010US20100136013 Cd55-interaction partners and the uses thereof
06/03/2010US20100136010 Novel 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
06/03/2010US20100136009 OVR110 Antibody Compositions and Methods of Use
06/03/2010US20100136008 TACI-Fc Fusion Proteins, Methods of Making and Uses Thereof
06/03/2010US20100136006 Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
06/03/2010US20100136000 Treatment of follicular lymphomas using inhibitors of the lt pathway
06/03/2010US20100135999 Quinoline-carboxamide derivatives as p2y12 antagonists
06/03/2010US20100135998 Combination therapy for treatment of immune disorders
06/03/2010US20100135996 Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type ii receptor (amhr-ii)
06/03/2010US20100135993 Method of treating malignant mesothelioma
06/03/2010US20100135991 Antibodies recognizing oxygen-regulated protein 150 expressed on cancer cells and methods of using same
06/03/2010US20100135985 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them an uses thereof
06/03/2010US20100135984 Anti-inflammatory compositions and methods
06/03/2010US20100135980 Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging, disorders of aging, cancer, as growth factors, and as an alternative to stem cell therapy
06/03/2010US20100135975 CD133 Epitopes
06/03/2010US20100135973 Microorganism Strain CRC2631 of Salmonella typhimurium and its Use as a Cancer Therapeutic
06/03/2010US20100135969 Method of treating cancer using platelet releasate
06/03/2010US20100135958 Method for treating cancer in humans
06/03/2010US20100135957 Chimeric Heteromultimer Adhesins
06/03/2010US20100135956 Steroid modulators of progesterone receptor and/or glucocorticoid receptor
06/03/2010US20100135954 6-Phenylpyrimidinones as PIM Modulators
06/03/2010US20100135905 Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
06/03/2010US20100135904 Compositions and methods for the inhibition of cripto / grp78 complex formation and signaling
06/03/2010US20100135903 Use of a dna damaging agent and a ligand for the treatment of cancer
06/03/2010US20100135902 Papillomavirus pseudoviruses for detection and therapy of tumors
06/03/2010US20100135901 Combination therapy
06/03/2010CA2777638A1 Genetic variants useful for risk assessment of thyroid cancer
06/03/2010CA2750147A1 Anticancer composition comprising antitumor agent and substance having inhibitory effects on l1cam activity and expression
06/03/2010CA2745012A1 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
06/03/2010CA2745005A1 Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
06/03/2010CA2745004A1 Pyridine-3-carboxyamide derivative
06/03/2010CA2744996A1 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
06/03/2010CA2744990A1 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
06/03/2010CA2744937A1 Hsp90 inhibitor combinations
06/03/2010CA2744833A1 Benzonaphtyridine compounds as inhibitors of autotaxin
06/03/2010CA2744828A1 Five crystal forms, methods of preparation, pharmaceutical compositions and applications of 3-(3'-carboxy-4'-hydroxy-anilino-carbo-)-6-nitro-7-hydroxy-8-methyl-coumarin)>>
06/03/2010CA2744823A1 Treating neoplasms with neurotoxin
06/03/2010CA2744449A1 Methods for the treatment of infections and tumors
06/03/2010CA2744369A1 2-(n-substituted piperazinyl) steroid derivatives
06/03/2010CA2744360A1 Hybrid -ionone and curcumin molecules as anticancer agents
06/03/2010CA2744178A1 Indole derivatives, method for preparing same and pharmaceutical compositions containing same
06/03/2010CA2743722A1 Hsp90 inhibitors for therapeutic treatment
06/03/2010CA2743097A1 Regioselective reduction of fused pyrrolocarbazoles -5,7-diones
06/03/2010CA2743030A1 3-aminocyclopentanecarboxamides as chemokine receptor modulators
06/03/2010CA2742539A1 Disubstituted phthalazine hedgehog pathway antagonists
06/03/2010CA2740975A1 Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
06/03/2010CA2739251A1 Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
06/02/2010EP2192190A1 Yogurt containing pectin hydrolysis products
06/02/2010EP2192188A1 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
06/02/2010EP2192179A1 Cdh3 peptide and medicinal agent comprising the same
06/02/2010EP2192131A1 Immunoglobulins devoid of light chains
06/02/2010EP2192130A1 Human DR4 antibodies and uses thereof
06/02/2010EP2192120A1 Stable crystalline salt of 5-methyll-(6S)-tetrahydrofolic acid
06/02/2010EP2192114A1 bis [O-(14-benzoylaconine-8-yl)] esters
06/02/2010EP2192108A1 Novel dihydronaphthalene compound and use thereof
06/02/2010EP2191843A1 Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
06/02/2010EP2191842A1 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
06/02/2010EP2191841A1 Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
06/02/2010EP2191840A1 Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
06/02/2010EP2191839A2 Immunogenic LHRH compositions and methods relating thereto
06/02/2010EP2190994A2 Compositions comprising stat3 sirna and methods of use thereof
1 ... 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 ... 2211